← Back to screener

TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA

Rank #2241 · NYSE · $49.0B market cap
Audited by Kesselman & Kesselman, no going-concern flag in the latest filing.
Score
27.7
P/E
-87.7
P/B
9.12
ROE
-10.4%
Op. Margin
2.7%
Debt Ratio
625%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -87.7x, P/B 9.12x. Ranks in the top 74% of the universe.

Profitability ★☆☆☆☆
Weak

ROE -10.4%. Ranks in the top 71% of the universe.

Safety ★☆☆☆☆
Poor

Debt ratio 625%. Ranks in the top 83% of the universe. Above 200% signals meaningful leverage risk.

Growth ★★★☆☆
Average

Revenue growth of 6.2% year over year. Ranks in the top 45% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2017–$3.4B$1.6B$33.3B–174
2018$21.9B$2.2B$0.3B$17.4B9.8299
2019$21.9B$-17.5B$-16.3B$14.7B-80.0305
2020$18.3B$-1.6B$-2.1B$14.0B-9.0304
2021$16.9B$-0.4B$-1.0B$10.0B-2.6395
2022$16.7B$-3.6B$-4.0B$10.3B-21.4354
2023$15.9B$1.7B$0.4B$7.8B10.8463
2024$14.9B$-2.2B$-2.4B$7.5B-14.7471
2025$15.8B$0.4B$-0.6B$5.4B2.7625

← See the full screener